Search research articles
Contact Us
Filters
Showing results (41-50 of 47) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 47 results.
Neurology
|
March 6, 2024
Comparative Effectiveness of Natalizumab, Fingolimod, and Injectable Therapies in Pediatric-Onset Multiple Sclerosis: A Registry-Based Study
Tim Spelman, Gabrielle Simoneau, Robert Hyde, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|
March 13, 2026
The real-world effectiveness and safety of off-label rituximab in a large cohort of Middle Eastern multiple sclerosis patients
Ghida Ismail, Maya Zeineddine, Raed Al-Roughani, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
June 1, 2025
Comparative effectiveness of natalizumab and anti-CD20 monoclonal antibodies in relapsing-remitting multiple sclerosis: a real-world propensity-score matched study
Bassem Yamout, Raed Alroughani, Samar Frouk Ahmed Mohamed, et al.
Multiple Sclerosis and Related Disorders
|
March 14, 2020
Neuromyelitis optica spectrum disorders in Arabian Gulf (NMOAG); establishment and initial characterization of a patient registry
Eslam Shosha, Abdulla Al Asmi, Eman Nasim, et al.
Frontiers in Neurology
|
January 8, 2024
Predictors of treatment switching in the Big Multiple Sclerosis Data Network
Tim Spelman, Melinda Magyari, Helmut Butzkueven, et al.
Journal of Neurology
|
February 3, 2026
Effect of late-onset on multiple sclerosis phenotype and outcome: evidence from a multi-national registry
Amira Souissi, Francesco Patti, Tim Spelman, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
February 28, 2023
Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis
Cyrus Daruwalla, Vahid Shaygannejad, Serkan Ozakbas, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 47) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 47 results.
Neurology
|
March 6, 2024
Comparative Effectiveness of Natalizumab, Fingolimod, and Injectable Therapies in Pediatric-Onset Multiple Sclerosis: A Registry-Based Study
Tim Spelman, Gabrielle Simoneau, Robert Hyde, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|
March 13, 2026
The real-world effectiveness and safety of off-label rituximab in a large cohort of Middle Eastern multiple sclerosis patients
Ghida Ismail, Maya Zeineddine, Raed Al-Roughani, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
June 1, 2025
Comparative effectiveness of natalizumab and anti-CD20 monoclonal antibodies in relapsing-remitting multiple sclerosis: a real-world propensity-score matched study
Bassem Yamout, Raed Alroughani, Samar Frouk Ahmed Mohamed, et al.
Multiple Sclerosis and Related Disorders
|
March 14, 2020
Neuromyelitis optica spectrum disorders in Arabian Gulf (NMOAG); establishment and initial characterization of a patient registry
Eslam Shosha, Abdulla Al Asmi, Eman Nasim, et al.
Frontiers in Neurology
|
January 8, 2024
Predictors of treatment switching in the Big Multiple Sclerosis Data Network
Tim Spelman, Melinda Magyari, Helmut Butzkueven, et al.
Journal of Neurology
|
February 3, 2026
Effect of late-onset on multiple sclerosis phenotype and outcome: evidence from a multi-national registry
Amira Souissi, Francesco Patti, Tim Spelman, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
February 28, 2023
Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis
Cyrus Daruwalla, Vahid Shaygannejad, Serkan Ozakbas, et al.
Page
of 5